UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Targeting the liver: Effects beyond obesity

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Targeting the liver: Effects beyond obesity

Naim Alkhouri 1

Affiliations

1 Transplant Hepatology Arizona Liver Health Phoenix, AZ, Phoenix, United States of America

Summary

AI Generated

The speaker presented liver-directed therapies for NASH, highlighting that resmetirom (thyroid hormone receptor beta agonist) and dual/triple incretin agonists targeting glucagon can improve liver fat, inflammation, and fibrosis through mechanisms beyond weight loss.

The speaker reported that in the Maestro NASH phase 3 trial, resmetirom achieved NASH resolution in up to 30% of patients and fibrosis improvement in up to 26% of patients with F2-F3 fibrosis treated for 52 weeks, with the drug receiving FDA and EMA approval in 2024.
Resmetirom targets thyroid hormone receptor beta selectively in the liver, increasing fatty acid oxidation and mitophagy while reducing LDL cholesterol and atherogenic lipids, according to the speaker.
The speaker stated that survodutide, a GLP-1 and glucagon dual agonist, showed fibrosis improvement with up to 30% delta from placebo in a 48-week study, with mediation analysis indicating fibrosis benefits were mainly weight loss independent.
In the SYNCHRONIZE-NAFLD phase 3 study, the speaker reported that close to 85% of patients treated with survodutide achieved at least 30% relative reduction in liver fat and 61% normalized liver fat to less than 5%.
The speaker noted that resmetirom can be safely combined with GLP-1 agents without drug-drug interactions, as demonstrated in Maestro NASH where up to 15% of patients were on stable-dose GLP-1 therapy.
The speaker recommended that both liver specialists and endocrinologists should be comfortable prescribing these therapies and monitoring multiple organ systems in patients with metabolic disease.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Hepatobiliary Small Intestine & Nutrition Mechanisms & Personalised Medicine

Session

Therapy update: Anti-obesity

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Guiding the care of hypertriglyceridemia-induced acute pancreatitis: Multidisciplinary care and the role of new therapies through apoC-III inhibition (Sobi (Swedish Orphan Biovitrum)) (Complete Session)

Clara Viñals

DOES TIMING MATTER? PLASMA EXCHANGE IN HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS: MONOCENTRIC STUDY

Ghizlane Kharrasse

CHARACTERISTICS OF SUBACUTE AND CHRONIC INTESTINAL FAILURE SECONDARY TO INFLAMMATORY BOWEL DISEASE IN A SPANISH COHORT: A NATIONAL MULTICENTER STUDY FROM YOUNG GETECCU GROUP

Yamile Zabana

The transition from acute to chronic pancreatitis: Can we stop it?

Bálint Erőss

SUSTAINED REAL-WORLD EFFECTIVENESS OF FILGOTINIB IN ULCERATIVE COLITIS: 12- AND 18-MONTH OUTCOMES FROM A MULTICENTRE COHORT (FILGUITO STUDY)

Federico Argüelles-Arias

Make IBD patients surgery ready

Stéphane Schneider

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Guiding the care of hypertriglyceridemia-induced acute pancreatitis: Multidisciplinary care and the role of new therapies through apoC-III inhibition (Sobi (Swedish Orphan Biovitrum)) (Complete Session)

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.